Evidence map›Paper›PMID 35140283›Full record

ArticleScientific reports2022

The fabrication and assessment of mosquito repellent cream for outdoor protection.

Hemanga Hazarika, Harshita Krishnatreyya, Varun Tyagi, Johirul Islam, Neelutpal Gogoi, Danswrang Goyary, Pronobesh Chattopadhyay, Kamaruz Zaman

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
6.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Potential of coconut oil as a mosquito repellent.Tropical medicine and health · 2025
    Article
  5. Review
  6. Article
  7. Frontiers in pharmacology · 2024
    Article
  8. Repellents againstFrontiers in insect science · 2024
    Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hemanga HazarikaDivision of Pharmaceutical Technology, Defence Research Laboratory, Tezpur, Assam, 784001, India. hemanga14@gmail.com.
Harshita KrishnatreyyaDivision of Pharmaceutical Technology, Defence Research Laboratory, Tezpur, Assam, 784001, India.
Varun TyagiEurofins Agroscience Services Pvt. Ltd., Tirupur, Tamil Nadu, 641603, India.
Johirul IslamCoromandel Int. Ltd., Shameerpet, Telangana, 500101, India.
Neelutpal GogoiDepartment of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, 786004, India.
Danswrang GoyaryDivision of Pharmaceutical Technology, Defence Research Laboratory, Tezpur, Assam, 784001, India.
Pronobesh ChattopadhyayDivision of Pharmaceutical Technology, Defence Research Laboratory, Tezpur, Assam, 784001, India. chattopadhyay.drl@gmail.com.
Kamaruz ZamanDepartment of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, 786004, India.
Defence Research Laboratory · INDibrugarh University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mosquito-borne infections like dengue, malaria, chikungunya, etc. are a nuisance and can cause profound discomfort to people. Due to the objectional side effects and toxicity associated with synthetic pyrethroids, N,N-diethyl-3-methylbenzamide (DEET), N,N-diethyl phenylacetamide (DEPA), and N,N-di ethyl benzamide (DEBA) based mosquito repellent products, we developed an essential oil (EO) based mosquito repellent cream (EO-MRC) using clove, citronella and lemongrass oil. Subsequently, a formulation characterization, bio-efficacy, and safety study of EO-MRC were carried out. Expression of Anti-OBP2A and TRPV1 proteins on mosquito head parts were studied by western blotting. In-silico screening was also conducted for the specific proteins. An FT-IR study confirmed the chemical compatibility of the EOs and excipients used in EO-MRC. The thermal behaviour of the best EOs and their mixture was characterized by thermogravimetric analysis (TGA). GC-MS examination revealed various chemical components present in EOs. Efficacy of EO-MRC was correlated with 12% N,N-diethyl benzamide (DEBA) based marketed cream (DBMC). Complete protection time (CPT) of EO-MRC was determined as 228 min. Cytotoxicity study on L-132 cell line confirmed the non-toxic nature of EO-MRC upon inhalation. Acute dermal irritation study, acute dermal dose toxicity study, and acute eye irritation study revealed the non-toxic nature of EO-MRC. Non-target toxicity study on Danio rerio confirmed EO-MRC as safer for aquatic non-target animals. A decrease in the concentration of acetylcholinesterase (AChE) was observed in transfluthrin (TNSF) exposed Wistar rats. While EO-MRC did not alter the AChE concentrations in the exposed animals. Results from western blotting confirmed that Anti-OBP2A and TRPV1 proteins were inhibited in TNSF exposed mosquitoes. Mosquitoes exposed to EO-MRC showed a similar expression pattern for Anti-OBP2A and TRPV1 as the control group. In silico study revealed eight identified compounds of the EOs play significant roles in the overall repellency property of the developed product. The study emphasizes the mosquito repellent activity of EO-MRC, which could be an effective, eco-friendly, and safer alternative to the existing synthetic repellents for personal protection against mosquitoes during field conditions.

Indexed as

AcetylcholinesteraseAnimalsCells, CulturedCell SurvivalCulicidaeCymbopogonDrug CompoundingEyeFemaleHumansInsect RepellentsMaleMolecular Docking SimulationOils, VolatilePlant OilsRabbitsAcetylcholinesteraseInsect Repellentslemongrass oilOils, VolatilePlant OilsTerpenes

Identifiers

PMID35140283
PMCPMC8828860
OpenAlexW4210916623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.